Abstract: Lipid modifying agents include 3-hydroxy-3-methylglutaryl coenzyme A ( HMGCoA ) inhibitor, phenoxy acetic acid derivative( fibrate), nicotinic acid and bile acid sequestrantwhich have different characteristics. HMG CoA inhibitor is the most used modifying agent. Antioxidantagents include natural antioxidant, such as vitamin C, vitamin E and β-carotene, andsynthetic antioxidant, fox example, probucol which is supported by considerable evidence-basedstudies. Thereby, we should depend on the results of evidence-based medicine, safety, efficiencyand economy when choosing lipid modifying agents and anti-atherosclerosis anti-oxidant agents.

Key words: Lipid modifying agent; Anti-oxidant agent; Atherosclerosis; Progress

摘要： 目前临床常用的调脂类药物包括3-羟-3-甲基戊二酰辅酶A还原酶（HMG CoA还原酶）抑制剂、苯氧乙酸衍生物（贝特类）、烟酸类和胆汁酸结合树脂，各类药物各有其特点，以HMG CoA还原酶抑制剂使用最为广泛；抗氧化类主要有天然抗氧化剂如VitC、VitE和β-胡萝卜素和合成抗氧化剂如普罗布考（又名丙丁酚），而后者的应用得到了大量循证医学证据的支持。因此，选用调脂与抗氧化类抗动脉粥样硬化药物应依据循证医学的结果，遵循安全、有效、经济的原则。

关键词: 调脂药; 抗氧化剂; 动脉粥样硬化; 进展